Charles Schwab Investment Management Inc Regulus Therapeutics Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 178,879 shares of RGLS stock, worth $293,361. This represents 0.0% of its overall portfolio holdings.
Number of Shares
178,879
Previous 178,879
-0.0%
Holding current value
$293,361
Previous $320,000
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding RGLS
# of Institutions
74Shares Held
56.5MCall Options Held
79.3KPut Options Held
20.3K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$21.1 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$10.6 Million0.78% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$8.2 Million1.15% of portfolio
-
Octagon Capital Advisors LP New York, NY4.26MShares$6.99 Million1.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.09MShares$6.71 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $24M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...